These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34994395)

  • 41. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Musashi2 as a novel predictive biomarker for liver metastasis and poor prognosis in colorectal cancer.
    Zong Z; Zhou T; Rao L; Jiang Z; Li Y; Hou Z; Yang B; Han F; Chen S
    Cancer Med; 2016 Apr; 5(4):623-30. PubMed ID: 26775684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
    Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M
    BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
    Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.
    Aasebø KØ; Dragomir A; Sundström M; Mezheyeuski A; Edqvist PH; Eide GE; Ponten F; Pfeiffer P; Glimelius B; Sorbye H
    Cancer Med; 2019 Jul; 8(7):3623-3635. PubMed ID: 31070306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.
    Lenos K; Goos JA; Vuist IM; den Uil SH; Delis-van Diemen PM; Belt EJ; Stockmann HB; Bril H; de Wit M; Carvalho B; Giblett S; Pritchard CA; Meijer GA; van Kooyk Y; Fijneman RJ; van Vliet SJ
    Oncotarget; 2015 Sep; 6(28):26278-90. PubMed ID: 26172302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CK7 and consensus molecular subtypes as major prognosticators in
    Loupakis F; Biason P; Prete AA; Cremolini C; Pietrantonio F; Pella N; Dell'Aquila E; Sperti E; Zichi C; Intini R; Dadduzio V; Schirripa M; Bergamo F; Antoniotti C; Morano F; Cortiula F; De Maglio G; Rimassa L; Smiroldo V; Calvetti L; Aprile G; Salvatore L; Santini D; Munari G; Salmaso R; Guzzardo V; Mescoli C; Lonardi S; Rugge M; Zagonel V; Di Maio M; Fassan M
    Br J Cancer; 2019 Oct; 121(7):593-599. PubMed ID: 31474758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.
    Nunes L; Aasebø K; Mathot L; Ljungström V; Edqvist PH; Sundström M; Dragomir A; Pfeiffer P; Ameur A; Ponten F; Mezheyeuski A; Sorbye H; Sjöblom T; Glimelius B
    Acta Oncol; 2020 Apr; 59(4):417-426. PubMed ID: 31924107
    [No Abstract]   [Full Text] [Related]  

  • 53. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL8 derived from macrophages inhibits CD8
    Zhao C; Wang D; Li Z; Zhang Z; Xu Y; Liu J; Lei Q; Han D; Huo Y; Liu S; Li L; Zhang Y
    Int Immunopharmacol; 2023 Aug; 121():110457. PubMed ID: 37331296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer.
    Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T
    In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer.
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Iseki Y; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
    In Vivo; 2018; 32(1):151-158. PubMed ID: 29275313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
    Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
    J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.